就像大型生物技术公司健赞的首席执行官亨利·特米尔(HenriTermeer)所说，“随着时间的推移，个人化药物的推出，依靠拳头产品的商业模式变得越来越不重要了。”
As Henri Termeer, chief executive of Genzyme, a big biotechnology firm, argues, “the blockbuster model becomes less important over time as specialised therapies take off.”
就像大型生物技术公司健赞的首席执行官亨利·特米尔(HenriTermeer)所说，“随着时间的推移，个人化药物的推出，依靠拳头产品的商业模式变得越来越不重要了。”
As Henri Termeer, chief executive of Genzyme, a big biotechnology firm, argues, “the blockbuster model becomes less important over time as specialised therapies take off.”
应用推荐